If you are interested, please contact us!
Ovarian cancer is the sixth most common type of cancer amongst females in the UK. There are around 20 new cases diagnosed every day - around 7500 new cases per year. With around 11 ovarian cancer deaths per day in the UK, ovarian cancer accounted for about 5% of all cancer deaths in females in the UK. But, more than a third of women diagnosed with ovarian cancer survive over 10 years.
Like all types of cancer, the earlier the diagnosis the better the prognosis. Currently the diagnosis of ovarian cancer can be a protracted process for a patient involving scans, a blood test, biopsy and laparoscopy. Could there be a better way? Well a group of scientists from Japan certainly hope so. In a paper published online in the journal Oncology Lettersthey set out the details of a study into the potential of using biomarkers to identify malignant ovarian tumours and chromatography played a significant role.
This is the end of the introduction of Chromatography Finds a Potential Biomarker for Ovarian Cancer. I hope it can help you.
C-Mannosyl tryptophan (CMW) is a glycosylated amino acid that can be used as a biomarker for renal dysfunction. The team behind the paper referenced above investigated if there were changes in blood CMW levels in patients with ovarian cancer versus healthy controls. They analysed 49 plasma samplers from patients with ovarian cancer and 7 from healthy individuals using HPLC(HPLC analysis). The use of chromatography to analyse samples of amino acids and proteins is discussed in the article.